Matthew ‘Matt’ Wayne Johnson is an Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University. His research is concerned with addiction medicine, drug abuse, and drug dependence.
CV of Matthew Johnson
From his bio: “Matt published psychedelic risk and safety guidelines in 2008, helping to resurrect human psychedelic research. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in treating cancer distress in 2016.”
Matt Johnson is one of the most active researchers in the psychedelics field at this moment. He has recently been given the first psychedelic (in the name) professorship endowment. The ‘Susan Hill Ward Professor in Psychedelics and Consciousness at Johns Hopkins’.
Part of his research is being funded by the Beckley Foundation (article).
He is also a member of the scientific advisory board of MindMed, AWAKN, Beckley Psytech, Entheon, and Silo Pharma.
And also advises Entheogen Biomedical, Field Trip, Otsuka Pharmaceutical.
Matt is also active on Twitter where he has one of the best biographies you can think of “Professor at Johns Hopkins studying uppers (cocaine, nicotine, meth), downers (alcohol), all-arounders (psychedelics).”
Media
- Dr. Matthew Johnson Joins AWAKN Life Sciences (press release, September 2020)
- INSIGHT 2019: Therapeutic Effects of Psilocybin (Matthew Johnson) (Insight, 2019)
- Matthew W. Johnson: Psychedelic Research at Johns Hopkins (Colloquium on Psychedelic Psychiatry, 2018)
Explore more info with a membership (any level)
🧑 Extended profile information
📈 In-depth psychedelic reports (Sprout & Tree)
🪄 Weekly psychedelic research & implementation newsletter (free)